Inovio and Wistar team up for DNA-based immunotherapies
16 March 2016 | By Victoria White
Inovio and the Wistar Institute are to research preventive and therapeutic DNA-based immunotherapies for cancers and infectious diseases...
List view / Grid view
16 March 2016 | By Victoria White
Inovio and the Wistar Institute are to research preventive and therapeutic DNA-based immunotherapies for cancers and infectious diseases...
15 March 2016 | By Victoria White
Under a collaboration with Roche, Blueprint Medicines will lead preclinical research and development through to Phase I proof of concept...
10 March 2016 | By Victoria White
PhoreMost has entered into an alliance with The Wistar Institute to identify and de-orphan novel targets in cancer, aging and the immune system...
4 March 2016 | By Victoria White
Researchers have found the tools necessary to give immunotherapy the precision guidance that patients with cancer so desperately need...
3 March 2016 | By Victoria White
Combined with chemotherapy, a novel cell-based immunotherapy drastically increased the survival rates of mice afflicted with brain tumours. Almost 50% of the mice were completely cured...
Recombinant monoclonal antibodies or antibody biologics have been successfully developed as diagnostic and therapeutic agents...